Clinical Trial Update: Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This update describes a Phase 1 study of amivantamab, a bispecific EGFR and cMet antibody, in participants with advanced non-small cell lung cancer and provides…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Non-Small-Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING